Current Cardiology Reports

, Volume 4, Issue 5, pp 434–440

Interactions of antiarrhythmic drugs and implantable devices in controlling ventricular tachycardia and fibrillation

Authors

  • Yadavendra S. Rajawat
    • University of Pennsylvania
  • Darryl Dias
    • University of Pennsylvania
  • Edward P. Gerstenfeld
    • University of Pennsylvania
  • Sanjay Dixit
    • University of Pennsylvania
  • Bindi Shah
    • University of Pennsylvania
  • Andrea M. Russo
    • University of Pennsylvania
  • Francis E. Marchlinski
    • University of Pennsylvania
Article

DOI: 10.1007/s11886-002-0044-2

Cite this article as:
Rajawat, Y.S., Dias, D., Gerstenfeld, E.P. et al. Curr Cardiol Rep (2002) 4: 434. doi:10.1007/s11886-002-0044-2

Abstract

Implantable cardioverter defibrillators (ICDs) have proven highly successful in the treatment of life-threatening ventricular arrhythmias. Despite the efficacy of the ICD in terminating ventricular arrhythmias, antiarrhythmic drugs remain an important adjunct to ICD therapy. The use of antiarrhythmic drug therapy in combination with the ICD is synergistic in terms of beneficial effects, but also has the potential for some adverse interactions. Knowledge and recognition of these potential interactions is important for any physician managing patients with an ICD. This review summarizes the benefits and adverse effects of ICD in combination with antiarrhythmic drug therapy, and provides guidelines to ensure safe application of this hybrid therapy.

Copyright information

© Current Science Inc 2002